Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial

BACKGROUND: Fumaric acid esters (FAEs; Fumaderm(®)) are the most frequently prescribed first‐line systemic treatment for moderate‐to‐severe plaque psoriasis in Germany. Risankizumab (Skyrizi(®)) is a humanized IgG1 monoclonal antibody that specifically binds to the p19 subunit of interleukin 23. OBJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaçi, D., Eyerich, K., Pinter, A., Sebastian, M., Unnebrink, K., Rubant, S., Williams, D. A., Weisenseel, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291944/
https://www.ncbi.nlm.nih.gov/pubmed/33991341
http://dx.doi.org/10.1111/bjd.20481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291944/
https://www.ncbi.nlm.nih.gov/pubmed/33991341
http://dx.doi.org/10.1111/bjd.20481

Ejemplares similares